On March 18, 2026 STADA reported that in 2025 again demonstrated the success of its three-segment strategy, that provides patients and healthcare professionals with a broad range of medicines and healthcare products across Consumer Healthcare, Generics and Specialty, including innovative medicines.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Adjusted, constant-currency (adj. cc) Group revenues increased by 6% to €4.3 billion in the financial year ended 31 December 2025. Group earnings before interest, tax, depreciation and amortization (EBITDA) ̵ adjusted for special items and at constant exchange rates ̵ improved by 8% to €961 million.

"All our regions ̵ Western Europe, Central & Eastern Europe, Germany and Middle East & Asia ̵ are contributing nicely to our growth. Key drivers for our above-industry growth were several great launches across all our three segments. On top of this, we in-licensed in 2025 alone 110 new products securing an even stronger pipeline for a successful future," commented STADA CEO Peter Goldschmidt.

(Press release, Stada, MAR 18, 2026, View Source [SID1234670887])